| Literature DB >> 32483756 |
K V Derkach1, A A Bakhtyukov1, V N Sorokoumov2, A O Shpakov3.
Abstract
Thyroid stimulating hormone (TSH) receptor antagonists are required for the treatment of TSH-dependent tumors and Graves disease. We developed the compound 5-amino-N-(tert-butyl)-4-(4-iodophenyl)-2-(methylthio)thieno[2,3-d]pyrimidine-6-carboxamide (TP48) and showed that it reduces the TSH-stimulated adenylate cyclase activity in rat thyroid membranes. Pretreatment of rats with compound TP48 (ip, 40 mg/kg) reduced the increase in the levels of total and free thyroxin in blood and the increase in the expression of thyroglobulin and D2 deiodinase genes in the thyroid gland, which are responsible for the synthesis of thyroid hormones, which were caused by intranasal administration of thyroliberin to animals (300 μg/kg). These data indicate that compound TP48 is a functional antagonist of the TSH receptor and can be used to correct the thyroid status in hyperthyroidism.Entities:
Keywords: thyroid stimulating hormone receptor, antagonist, thienopyrimidine, thyroid gland
Mesh:
Substances:
Year: 2020 PMID: 32483756 DOI: 10.1134/S1607672920020064
Source DB: PubMed Journal: Dokl Biochem Biophys ISSN: 1607-6729 Impact factor: 0.788